IL-1 inhibitors that are currently tested in clinical trials for SJIA, AOSD, KD, IRP, BS or Crystal-induced Arthropathies, such as gout or CPDD, include anakinra, rilonacept, and canakinumab. Here, IL1A is linked to adult-onset Still disease.